---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014648"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T14:17:33.311540+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 shows dose-dependent reversal of Wilson's disease symptoms in animal model

## Summary
- Up to 4-5x reduction in episodic tremor events; normalization of swim and exploratory behavior.
- Approximately 50% reduction in copper accumulation in dry liver tissue.
- ALT, AST, bilirubin restored to normal levels, indicating protection of liver function.
- Significant improvement in liver and kidney histopathology scores to near-normal.
- IND submission planned by year-end; human clinical trials targeted for H1 2026.

## SEC filing metadata
- accession: 0001641172-25-014648
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225014648/0001641172-25-014648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225014648/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014648
- JSON: https://secwatch.observer/filing/0001641172-25-014648.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014648.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.